By Chris Wack
MAIA Biotechnology's shares rose 19% to $2.46 after the company said it entered into a clinical supply agreement with BeiGene to evaluate THIO, MAIA's telomere-targeting anticancer agent.
The clinical-stage biopharmaceutical company said THIO will be used alongside BeiGene's tislelizumab in three cancer types: hepatocellular carcinoma, small cell lung cancer, and colorectal cancer.
The trials will test the combination's efficacy in single-arm Phase 2 studies.
MAIA will fund and sponsor the trials, retaining global rights to THIO while BeiGene supplies tislelizumab. The Chicago-based company is trying to get accelerated Food and Drug Administration approvals for these indications.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
January 07, 2025 13:05 ET (18:05 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。